Anokion Presents Phase 1 MoveS-it Study Data on ANK-700 for Relapsing-Remitting MS

New Findings Presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Research from the Phase 1 MoveS-it Study Shows the Safety and Biological Activity of ANK-700 as a Potential Disease-Modifying Treatment for Relapse-Remitting Multiple Sclerosis

CAMBRIDGE, MA, USA & LAUSANNE, Switzerland, September 18, 2024

Anokion SA, a biotechnology company focused on autoimmune disease treatment through immune tolerance restoration, announced the upcoming presentation of new data at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). This event is scheduled from September 18-20, 2024 in Copenhagen, Denmark.

The data includes pre-clinical and clinical findings from Anokion's Phase 1 MoveS-it study, which evaluates the safety and tolerability of ANK-700 in 34 patients aged 18-60 with relapse-remitting multiple sclerosis (RRMS) across the United States.

"We are excited to share these promising findings at ECTRIMS, highlighting ANK-700's potential as a novel disease-modifying intervention for RRMS," said Deborah Geraghty, Ph.D., CEO of Anokion. "ANK-700 is an investigational therapy featuring a novel myelin immuno-domain conjugated to a glycosylation signature. It is designed to re-educate the immune system by inducing antigen-specific tolerance to myelin-based autoantigens. This aims to reduce neuroinflammation in the brain and spinal cord while preserving overall immune function. The data being presented shows clinical proof of concept, safety, and biological activity of ANK-700, emphasizing its potential as a differentiated, safe, and tolerable treatment option for RRMS."

The new data contributes to Anokion’s expanding immune tolerance clinical dataset, utilizing its proprietary immune tolerance platform. Single doses of ANK-700 up to 3.0 mg/kg and multiple doses up to 1.0 mg/kg were found to be safe and well-tolerated, with no Serious Adverse Events (SAEs) related to the treatment. Additionally, there was no clinical or MRI evidence of disease exacerbation. The company will also present encouraging mechanistic data demonstrating the tolerization of myelin-reactive T-cells and bystander suppression, further supporting ANK-700's potential in treating RRMS.

Anokion will also showcase pre-clinical data demonstrating that its liver-targeted antigen approach effectively expands antigen-specific regulatory T-cells in vivo. This offers therapeutic potential across various inflammatory conditions, including multiple sclerosis, where multiple antigens could be driving the disease.

About Anokion

Anokion SA is a clinical-stage Swiss biotechnology company dedicated to making a significant difference in the lives of patients with autoimmune diseases by restoring normal immune tolerance. The company focuses on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. Anokion’s unique approach leverages its immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the root cause of autoimmune diseases.